November 2017
Lucy Turnbull quietly exits sole ASX role
Last Friday at the Prima Biomed AGM, Lucy Turnbull used her chairman's address to announce that she was leaving the company the next day. Not that anyone noticed.
- Updated
- Myriam Robin
September 2015
Message to Malcolm Turnbull: use our top quality medical research for economic benefit
We know Malcolm Turnbull is no Luddite. But can he revitalise Australian medical science and ensure that research is commercialised in Australia rather than overseas.
- Updated
- Ian Gust and Jan Tennent
Liberal leadership: Lucy Turnbull gives Prima BioMed and SeaLink line to the Lodge
Two Australian listed small-cap companies, Prima BioMed and Sealink Travel Group, have a senior board director who is set to double as the country's next "first lady".
- Updated
- Jessica Gardner
August 2015
Scared Australian investors miss out on big biotech returns
US investors are snapping up promising Australian biotech firms, while Australian fund managers who don't understand the sector stick to blue-chip stocks like banks, miners, telcos and utilities.
- Updated
- John Kehoe
October 2014
Prima Biomed looking for a second chance
Biotechnology company, Prima Biomed is looking for its silver lining with the acquisition of French biopharmaceutical company Immutep SA for $US28 million.
- Su-Lin Tan
April 2014
Local venture capital market lacks depth
When Gina Rinehart’s son John Hancock this week joined the advisory board of a New York-based Lind Partners he signalled his support for bringing in foreign capital to support Australia’s junior miners.
- Updated
- Tony Boyd
November 2013
Prima BioMed narrows cancer trial focus with hopes of success
After a weak clinical trial result that wiped more than half of Prima BioMed’s value, chief executive Matthew Lehman is pinning his hopes on a smaller group of patients.
- Updated
- Jessica Gardner
September 2013
Lucy Turnbull down $728,142 in a day
It was a sweet and sour Thursday for the Turnbulls. Malcolm and Lucy Turnbull’s daughter, Daisy, had a baby boy – but while their personal life sung, business was less than stellar.
- Updated
June 2013
2013 a tough year for small caps
The past 12 months have been a miserable affair for many small caps, with the index now trading at its lowest point since April 2009.
- Updated
- Sally Rose
October 2012
- Opinion
- Opinion
Eyes on Prima BioMed’s vaccine update
Biotech company Prima BioMed is set to reveal some interim data on its Phase 11b trial for its chief ovarian cancer vaccine today.
- Sarah Thompson and Anthony Macdonald
January 2012
- Opinion
- Opinion
US success may lift Prima
Prima BioMed will likely get a boost today after US Dendreon Corp, maker of the prostate-cancer drug Provenge, jumped 39pc after reporting stronger fourth-quarter sales.
- Updated
- Sarah Thompson and Stephen Shore
June 2011
Healthy interest helps Prima BioMed top raisings
Prima BioMed topped capital raisings on Tuesday after it announced a recent share purchase plan had closed oversubscribed and raised $20.3 million. Other raisers on Tuesday included Matilda Zircon, Mint Wireless and Two Way.
- Updated
- Anthony Macdonald
Prima Biomed
Big things are being tipped for biotechnology company Prima Biomed. The stock has surged more than 175 per cent over the past 12 months.
- Updated
Biotech stocks guilty by association
This has been a tough period for small-cap investors, but some sectors have taken an added blow due to a dismal update by a major player in that space.
- Updated
- Brendon Lau
May 2011
Prima Biomed raising takes No. 1 spot on Wednesday
Prima Biomed topped capital raisings on Wednesday with a $38 million placement and share purchase plan to fund ongoing testing and development of an ovarian cancer vaccine.
- Updated
- Anthony Macdonald
May 2010
Brief: Prima BioMed
Prima BioMed has an agreement with the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig, Germany, to produce Prima’s CVac cancer immunotherapy product for the European clinical trials.